Tesamorelin for Visceral Fat: Body Composition Effects Explained

Tesamorelin is a synthetic growth hormone-releasing hormone (GHRH) analog that, in randomized human trials, selectively reduced visceral adipose tissue (VAT) by roughly 15–18% in adults with HIV-associated lipodystrophy. It is FDA-approved only for that population, not for general weight loss. This guide reviews the body-composition evidence, mechanism, dosing parameters, and safety.

Tesamorelin at a glance

• Class: synthetic 44-amino-acid GHRH analog (growth hormone secretagogue)
• Brand names: Egrifta, Egrifta SV, Egrifta WR (Theratechnologies)
• Commonly cited dose (FDA label): 2 mg subcutaneous, once daily
• Best-studied for: reduction of excess visceral abdominal fat in HIV-associated lipodystrophy
• Typical study duration: 26–52 weeks
• Reported VAT reduction: ~15.2% vs. placebo in the pivotal trial (Falutz et al., NEJM 2007)
• FDA status: approved (Nov 2010); newest formulation Egrifta WR approved March 25, 2025
• Not approved for: general weight loss, non-HIV populations, or cosmetic fat reduction

What is tesamorelin?

Tesamorelin is a stabilized analog of human growth hormone-releasing hormone (GHRH). Structurally, it is the full 44-amino-acid sequence of endogenous GHRH with a trans-3-hexenoic acid group attached to the N-terminus. That modification resists breakdown by the enzyme dipeptidyl peptidase-IV (DPP-IV), extending the molecule's half-life while preserving its activity at the GHRH receptor (Bedimo, HIV AIDS (Auckl) 2011).

Unlike injected recombinant growth hormone, tesamorelin does not deliver growth hormone (GH) directly. Instead, it prompts the pituitary gland to release the body's own GH in a more physiologic, pulsatile pattern. The result is a downstream rise in insulin-like growth factor-1 (IGF-1). Tesamorelin was the first — and remains the only — GHRH analog with active FDA approval in the United States, originally approved on November 10, 2010 under the brand name Egrifta (FDA i-Base summary, 2010).

Internally, GHRH analogs like tesamorelin and sermorelin sit in the broader GHRH/GHRP peptide family; if you are new to peptide terminology, start with our overview of what peptides are.

How does tesamorelin reduce visceral fat?

By stimulating endogenous GH release, tesamorelin raises circulating GH and IGF-1. Growth hormone is lipolytic — it promotes the breakdown of stored fat — and it appears to act preferentially on visceral (intra-abdominal) fat depots, which are metabolically active and densely populated with GH receptors.

In the pivotal phase III trial, IGF-1 levels rose by approximately 81% in the tesamorelin group versus a 5% decline on placebo (Falutz et al., N Engl J Med 2007). This restoration of the GH/IGF-1 axis is believed to drive the selective mobilization of visceral fat. Importantly, the effect is depot-specific: across trials, tesamorelin reduced VAT without producing meaningful reductions in subcutaneous adipose tissue (SAT) or overall body mass index — and it was associated with a gain in lean body mass rather than a loss.

This selectivity is the central reason tesamorelin is studied for body composition specifically, rather than as a general weight-loss agent. Visceral fat — not subcutaneous fat — is the depot most strongly linked to insulin resistance, dyslipidemia, and cardiometabolic risk.

What does the evidence show for body composition?

The strongest human evidence comes from randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy, a condition in which antiretroviral therapy can drive abnormal central fat accumulation.

Visceral fat. In the 26-week pivotal trial of 404 patients, VAT decreased by 15.2% in the tesamorelin group while increasing by 5.0% on placebo (Falutz et al., N Engl J Med 2007). A separate randomized trial reported a mean VAT reduction of 34 cm² (net treatment effect of −16.6% versus placebo) over 6 months (Stanley et al., JAMA 2014).

Pooled data. A 2026 meta-analysis of randomized controlled trials found a pooled mean VAT reduction of −27.71 cm² (95% CI −38.37 to −17.06; P < 0.001) and a mean increase in lean body mass of +1.42 kg (95% CI 1.13 to 1.71; P < 0.001), with no significant change in subcutaneous fat or BMI (Badran et al., Obes Res Clin Pract 2026).

Liver fat. Because visceral and hepatic fat are linked, several trials measured liver fat directly. In a randomized trial in HIV patients with NAFLD, tesamorelin reduced hepatic fat fraction by an absolute −4.1% (95% CI −7.6 to −0.7; P = 0.02) — about a 37% relative reduction — and 35% of treated participants normalized their liver fat versus 4% on placebo (Stanley et al., Lancet HIV 2019).

Durability. The VAT reduction is maintained as long as treatment continues. When tesamorelin is stopped, visceral fat tends to re-accumulate, indicating that the effect depends on ongoing therapy rather than producing a permanent change (Falutz et al., extension data, NEJM 2007).

A critical caveat: this evidence base is overwhelmingly in HIV-associated lipodystrophy. Robust randomized data in HIV-negative people seeking visceral-fat reduction for general health optimization are limited, and tesamorelin is not FDA-approved for that use.

What are the commonly cited dosing parameters?

The FDA-approved regimen, as described on the product label, is 2 mg of tesamorelin administered by subcutaneous injection once daily (Bedimo, HIV AIDS (Auckl) 2011). In clinical trials, most of the measurable change in visceral fat developed over 12–26 weeks of continuous daily use, with maintenance dosing thereafter.

Research and prescribing materials commonly cite the 2 mg daily figure because that is the dose studied in the registration trials. The newer Egrifta WR formulation simplifies preparation — it requires weekly reconstitution and a smaller injection volume than the older Egrifta SV — but the underlying daily-dosing schedule is preserved (Theratechnologies press release, March 25, 2025).

Dosing should never be self-directed. Tesamorelin is a prescription product, and individual factors (IGF-1 levels, glucose tolerance, comorbidities) determine whether it is appropriate. Consult your healthcare provider before starting any peptide protocol.

What are the side effects and safety considerations?

The most commonly reported adverse effects in trials and labeling are injection-site reactions (redness, itching, pain), joint pain (arthralgia), muscle pain, and fluid retention or swelling (edema) (WebMD/FDA labeling summary, 2025; Bedimo, HIV AIDS (Auckl) 2011).

Two metabolic signals deserve particular attention:

• IGF-1 elevation. Tesamorelin raises IGF-1, and a meaningful proportion of patients exceed the upper limit of normal. Because IGF-1 supports cell proliferation, clinicians monitor levels during therapy (Bedimo, HIV AIDS (Auckl) 2011).
• Glucose tolerance. FDA review materials noted a statistically significant increase in treatment-emergent diabetes in tesamorelin-treated patients versus placebo in pooled analyses, even though some long-term studies reported stable glucose over 52 weeks. Blood glucose monitoring is standard (Bedimo, HIV AIDS (Auckl) 2011).

Contraindications on the FDA label include disruption of the hypothalamic-pituitary axis (e.g., pituitary tumor or surgery, hypophysectomy, head irradiation), active malignancy, and pregnancy — the last because modifying visceral fat offers no benefit in pregnancy and animal data showed fetal harm (FDA prescribing information, 2025). Tesamorelin is explicitly not a weight-loss medication and has not been shown to improve cardiovascular outcomes.

Because these are serious considerations, screening, baseline labs, and ongoing monitoring matter. Review our general peptide safety basics and consult your healthcare provider before starting any peptide protocol.

Is tesamorelin legal? FDA and sourcing status

Tesamorelin is an FDA-approved prescription drug. The branded product Egrifta was first approved in November 2010; the current formulation, Egrifta WR (tesamorelin F8), received FDA approval on March 25, 2025 (Theratechnologies press release, 2025). FDA-approved tesamorelin therefore moves through the standard prescription channel rather than the research-chemical market.

Compounded tesamorelin is also supplied by some 503A and 503B compounding pharmacies, but the compounding landscape for peptides is in active flux. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet July 23–24, 2026 to evaluate several peptides for the 503A bulk drug substances list; the first meeting addresses substances such as BPC-157, semax, epitalon, TB-500, KPV, and MOTS-C, with additional peptides slated for a later meeting (FDA advisory committee calendar, 2026). The FDA has also signaled it does not intend to assign bulk substances nominated on or after January 7, 2025 to its interim compounding categories (FDA 503A bulk substances guidance). Tesamorelin's status as an FDA-approved drug is distinct from these compounding-bulk-list debates.

Legal status varies by jurisdiction; consult a lawyer for binding advice. For more on the compounding framework, see our 503A vs 503B peptide legality explainer.

How does tesamorelin compare to other GH secretagogues?

Tesamorelin is frequently contrasted with sermorelin and CJC-1295, which are also GHRH-based secretagogues. The key differentiators are the depth of evidence and regulatory status: tesamorelin has multiple randomized controlled trials and an FDA approval specifically for visceral-fat reduction, whereas most other GHRH analogs lack comparable phase III body-composition data. For a side-by-side, see our sermorelin vs. tesamorelin comparison. None of these agents is approved for cosmetic fat loss, and stacking decisions should involve a qualified provider.

Frequently asked questions

Q: Does tesamorelin reduce visceral fat in people without HIV? A: The randomized evidence for tesamorelin's visceral-fat effect comes almost entirely from adults with HIV-associated lipodystrophy, where it reduced VAT by roughly 15–18% versus placebo (Falutz et al., NEJM 2007). High-quality controlled data in HIV-negative people seeking visceral-fat reduction for general health are limited, and tesamorelin is not FDA-approved for that purpose. Anyone considering off-label use should discuss the risk-benefit balance with a healthcare provider.

Q: How much visceral fat can tesamorelin reduce? A: In the pivotal phase III trial, visceral adipose tissue fell by 15.2% in the tesamorelin group versus a 5.0% increase on placebo over 26 weeks (Falutz et al., NEJM 2007). A pooled meta-analysis found an average reduction of about 27.7 cm² of VAT (Badran et al., Obes Res Clin Pract 2026). Individual response varies, and the reduction reverses if treatment stops.

Q: Does tesamorelin cause weight loss? A: Not in the way most people expect. Tesamorelin selectively reduces visceral fat while increasing lean body mass, with little change in subcutaneous fat or overall BMI (Badran et al., Obes Res Clin Pract 2026). It is explicitly not approved or intended as a weight-loss medication. The benefit measured in trials is a shift in body composition, not scale weight.

Q: How long does tesamorelin take to work? A: In controlled trials, most of the measurable reduction in visceral fat developed over 12–26 weeks of daily use, and the benefit was maintained at 52 weeks with continued therapy (Falutz et al., NEJM 2007). Visceral fat tends to re-accumulate after discontinuation. Discuss realistic timelines and monitoring with your provider.

Q: Is tesamorelin FDA-approved? A: Yes — but narrowly. Tesamorelin (Egrifta) was first approved in November 2010 for reduction of excess abdominal fat in HIV-infected adults with lipodystrophy, and the newest formulation, Egrifta WR, was approved March 25, 2025 (Theratechnologies, 2025). It is not approved for general weight loss or for people without HIV.

Q: What are the main risks of tesamorelin? A: Commonly reported effects include injection-site reactions, joint and muscle pain, and fluid retention. More clinically important signals are elevated IGF-1 and an increased rate of treatment-emergent diabetes seen in pooled FDA review data (Bedimo, HIV AIDS (Auckl) 2011). It is contraindicated in active malignancy, pituitary disorders, and pregnancy. Always consult your healthcare provider before starting any peptide protocol.

Q: Does tesamorelin affect liver fat? A: Yes. In a randomized trial of HIV patients with NAFLD, tesamorelin reduced hepatic fat fraction by an absolute 4.1% (about a 37% relative reduction), and 35% of treated patients normalized their liver fat versus 4% on placebo (Stanley et al., Lancet HIV 2019). This mirrors its visceral-fat selectivity, since the two depots are metabolically linked.

References

1. Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370. PMID: 18057338. https://pubmed.ncbi.nlm.nih.gov/18057338/
2. Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389. https://jamanetwork.com/journals/jama/fullarticle/1889139
3. Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830. PMID: 31611038. https://pmc.ncbi.nlm.nih.gov/articles/PMC6981288/
4. Badran A, et al. Body composition, hepatic fat, metabolic, and safety outcomes of tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a meta-analysis of randomized controlled trials. Obes Res Clin Pract. 2026. PMID: 41545261. https://pubmed.ncbi.nlm.nih.gov/41545261/
5. Bedimo R. Growth hormone and tesamorelin in the management of HIV-associated lipodystrophy. HIV AIDS (Auckl). 2011;3:69–79. PMC3218714. https://pmc.ncbi.nlm.nih.gov/articles/PMC3218714/
6. Theratechnologies Inc. Theratechnologies receives FDA approval for EGRIFTA WR (tesamorelin F8). Press release, March 25, 2025. https://www.theratech.com/news-releases/news-release-details/theratechnologies-receives-fda-approval-egrifta-wrtm-tesamorelin/
7. U.S. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
8. U.S. FDA. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act